Skip to main content
Medical information Clinical review pending

Genetic Testing

ALPL Gene Hypophosphatasia Infantile Genetic Test

This genetic test identifies mutations in the ALPL gene, helping diagnose Hypophosphatasia, a rare metabolic disorder affecting bone development in infants. Early diagnosis supports timely management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Inform the laboratory of the patient's clinical history and any relevant family history.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ALPL Gene Hypophosphatasia Infantile Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Infants with unexplained bone fractures or pain
  • ✓Delayed growth and development in infancy
  • ✓Dental abnormalities present from birth
  • ✓Family history of Hypophosphatasia
  • ✓Suspected metabolic bone disorder
  • ✓Confirmation of clinical diagnosis
02

In plain language

What this test helps you understand

Diagnosis of Hypophosphatasia, a rare metabolic bone disorder caused by mutations in the ALPL gene. Early diagnosis facilitates appropriate management and monitoring.
The ALPL Gene Hypophosphatasia Infantile NGS Genetic DNA Test is a specialized genetic analysis designed to detect mutations within the ALPL gene. These mutations are the cause of Hypophosphatasia, a rare inherited metabolic condition that impacts bone mineralization and development. Identifying the condition early is important for managing symptoms and improving outcomes for affected infants.

This test uses Next Generation Sequencing (NGS) technology to examine the ALPL gene thoroughly. It looks for specific changes (mutations) that cause Hypophosphatasia, providing essential information for diagnosis and guiding medical care.

Parents or guardians of infants showing signs potentially related to Hypophosphatasia should discuss this test with their doctor. Symptoms can include unexplained bone fractures, bone pain, delayed growth, developmental delays, and dental issues. A family history of Hypophosphatasia is also a reason to consider testing.

Receiving a diagnosis allows for appropriate management strategies to be implemented. Understanding the genetic basis of the condition can also inform decisions about future family planning and provide insights into the potential progression of the disorder.

Results will indicate the presence or absence of mutations in the ALPL gene. Discussing these results with a healthcare professional or genetic counselor is crucial for understanding their meaning and implications for the child and family.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Inform the laboratory of the patient's clinical history and any relevant family history.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) analysis of the ALPL gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test primarily detects mutations within the ALPL gene. It may not detect all possible mutations, such as large deletions or duplications not detectable by NGS. Results should be interpreted in the context of the clinical presentation and family history. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Hypophosphatasia is a rare inherited metabolic disorder affecting bone and tooth mineralization due to deficient alkaline phosphatase activity, often caused by mutations in the ALPL gene.
Testing the ALPL gene helps confirm a diagnosis of Hypophosphatasia, especially in infants with suggestive symptoms like bone problems or developmental delays.
The test involves analyzing a sample of the infant's blood or DNA using Next Generation Sequencing (NGS) to look for specific mutations in the ALPL gene.
Results indicate whether specific mutations associated with Hypophosphatasia were found. A healthcare provider or genetic counselor should interpret the results in the context of the infant's clinical picture.
Yes, genetic counseling is highly recommended to help understand the test results, discuss the implications for the child and family, and explore options for management and family planning.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp